Reversal of threatening blindness after initiation of eculizumab in Purtscher-like retinopathy secondary to atypical hemolytic uremic syndrome by J. E. Ramos de Carvalho et al.
CASE REPORT
Reversal of threatening blindness after initiation of
eculizumab in Purtscher-like retinopathy secondary
to atypical hemolytic uremic syndrome
J. E. Ramos de Carvalho . R. O. Schlingemann . M. Oranje .
F. J. Bemelman . M. J. van Schooneveld
Received: 6 September 2016 / Accepted: 13 February 2017
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract Purtscher-like retinopathy, a rare manifes-
tation of systemic thrombotic microangiopathy, is a
potentially visually debilitating condition with no
effective proven treatment. Distinct pathogenic path-
ways have been proposed as etiological factors. We
revisit the etiology of Purtscher-like retinopathy based
on the rapid response and profound visual improve-
ment after initiation of systemic intravenous eculizu-
mab, an inhibitor of the complement cascade, in a
patient with Purtscher-like retinopathy secondary to
familial atypical hemolytic uremic syndrome (aHUS)
due to a mutation in complement factor H. We
hypothesize that the efficacy of eculizumab in this
patient provides evidence for pathogenic events in the
retina similar to those encountered in the renal
microvasculature of aHUS patients, namely comple-
ment-mediated thromboembolization as a result of
activation of the complement cascade in endothelial
cells with release of tissue factor and development and
amplification of a procoagulant state. To the best of
our knowledge, this is the first report in the literature of
eculizumab as an effective therapeutic strategy in
Purtscher-like retinopathy.
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Introduction
Purtscher and Purtscher-like retinopathy are rare,
often bilateral, multifactorial downstream occlusive
thromboembolic retinopathies, mediated in a large
proportion of cases by uncontrolled complement
activation. The designation Purtscher retinopathy
implies a traumatic etiology, whereas Purtscher-like
retinopathy depicts non-traumatic causes [1].
Several mechanisms have been brought forward as
hypothetical triggers of Purtscher and Purtscher-like
retinopathy [1–3]. Although the pathogenesis is likely
multifactorial and differs according to the underlying
predisposing condition, embolization of the retinal
microcirculation has been proposed as the common
pathogenic ground for the retinal findings [4–7].
Potential sources of toxic and/or obstructive emboli
include air, fat, fibrin, platelet and leukocyte aggre-
gates [1], emboli arising from orbital steroid injection
[8] and retrobulbar anesthesia [8–11], and amniotic
fluid emboli after childbirth [12]. Uncontrolled
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complement activation has been proposed to play a
major role in the pathogenesis of Purtscher-like
retinopathy by mechanisms involving endothelial
damage and activation of the clotting cascade
[5, 6, 13, 14] and development of leukocyte and
platelet aggregates [1, 4]. Other proposed mechanisms
include intravascular volume surge such as in sudden
expansion of retinal veins [1], hyperviscosity [15],
intracephalic shock waves such as in sudden increase
in intracranial pressure with resulting precapillary
occlusion at the level of the lamina cribrosa [16],
capillary endothelial damage [17] and vascular
endothelial dysregulation and ensuing endothelin-
induced vasculopathy [16]. Associated systemic enti-
ties include acute pancreatitis [18–25], pancreatic
adenocarcinoma [26], systemic lupus erythematosus
[27], renal failure [28, 29], amniotic fluid embolization
[12], thrombotic thrombocytopenic purpura [30–33],
hemolytic uremic syndrome (HUS) [31, 34] and
cryoglobulinemia [35–37]. In specific disorders, the
diagnosis of Purtscher-like retinopathy accompanies
multisystem organ failure and therefore portends a
poor prognosis [38].
Patients present with sudden visual acuity loss of
variable severity, hours to days after the onset of the
associated etiology. Some patients may be asymp-
tomatic which likely results in underreporting [4]. The
majority of cases (83–92%) show funduscopic evi-
dence of retinal nerve fiber layer infarcts (cotton-wool
spots) and intraretinal hemorrhages [1, 2]. Purtscher
‘‘flecken’’ corresponds to areas of intraretinal whiten-
ing with a clear zone (within 50 lm) on either side of
the retinal arterioles, venules and precapillary arteri-
oles. These lesions result from precapillary arteriolar
occlusion and, albeit pathognomonic, can be identified
in only 50% of cases [2]. Other less frequent findings
include macular edema, optic disk swelling and a
pseudo-cherry red spot. Fluorescein angiography
shows evidence of an occlusive thromboembolic
retinopathy with areas of retinal non-perfusion and
leakage of dye from retinal arterioles, capillaries,
venules and optic disk [4].
Up to 40% cases may be associated with normal-
ization of all retinal findings and restoration of normal
visual acuity; however, a significant proportion of
patients develop optic atrophy, mottling of the retinal
pigment epithelium (RPE), retinal thinning and nar-
rowing of retinal arteries [4, 39]. The prognosis for the
individual patient is difficult to predict due to the lack
of clear and validated predictors. Treatment strategies
range from watchful waiting, plasmapheresis or high
dose systemic corticosteroids [2, 40–42].
Hemolytic uremic syndrome is characterized by
non-immune hemolytic anemia, thrombocytopenia
and renal impairment. Most cases (90%) are secondary
to infection with Shiga toxin-producing bacteria as
well as other bacteria, such as Streptococcus pneumo-
niae [43]. Non-infectious causes, classified as atypical
hemolytic uremic syndrome (aHUS), are linked to
uncontrolled complement activation. The familial
type of aHUS has a particularly poor prognosis, with
progression to end-stage disease occurring in 50 and
80% of cases [44]. Purtscher-like retinopathy has been
reported to occur in a minority of patients with HUS
[45–47].
We present a case of Purtscher-like retinopathy
secondary to aHUS due to complement factor H
(CFH) mutation and resulting complement overacti-
vation, successfully treated with systemic intravenous
administration of eculizumab (Soliris; Alexion Phar-
maceuticals, Cheshire, CT, USA), an inhibitor of
terminal complement activation. We hypothesize that
eculizumab may be an alternative therapeutic strategy
for severe Purtscher-like retinopathy associated with
deregulated activation of the complement pathway.
Based on the response achieved after initiation of
treatment, an alternative etiology for Purtscher-like
retinopathy is proposed after a short review of the
literature.
Case description
A 20-year-old Caucasian woman presented with
complaints of subacute painless loss of vision of her
left eye. She was referred to our clinic for intravitreal
ganciclovir treatment after a putative diagnosis of
bilateral cytomegalovirus retinitis had been made by
an ophthalmologist at her local hospital the previous
day. She was one of three sisters with familial aHUS
due to a missense mutation (c.3572 C[T, Ser1191-
Leu) in exon 23 of Complement Factor H (CFH gene).
At 6 years of age, she underwent bilateral nephrec-
tomy followed 1 year later by a living donor renal
transplant. After 1 year, she developed a systemic
cytomegalovirus infection with relapse of aHUS. Her
immunosuppression was tapered to a calcineurin-free
regimen, and chronic maintenance plasmapheresis
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was started. Four years later, a transplant biopsy
showed chronic allograft nephropathy with global
glomerulosclerosis and tubular atrophy. There were no
treatment options other than supportive care and her
renal function slowly declined hereafter. At 19 years
of age, she reached end-stage renal failure, immuno-
suppression was further tapered and she was started on
dialysis. The maintenance plasmaphereses were
halted. During dialysis, she complained of seeing
‘‘black spots’’ and was referred to a local ophthalmol-
ogist who in turn referred her to our service. Her
family history included two sisters, one of them her
identical twin, with aHUS and CFH mutation. Her
brother was an asymptomatic carrier for the CFH
mutation, and her younger sister was not affected. She
had no past history of ocular illnesses.
On ophthalmologic examination, best corrected
visual acuity was 20/15 and 20/200-2 in the right and
left eyes, respectively. There was no relative afferent
pupillary defect. Intraocular pressure was normal. The
anterior chambers and vitreous were clear in both
eyes. Fundus examination revealed cotton-wool spots
and mild flame-shaped hemorrhages in both eyes. The
left eye showed mild macular cystoid macular edema.
The retinal vessels were of a normal caliber in both
eyes. An inconspicuous choroidal nevus was present
in the nasal retina of the right eye. Fluorescein
angiography revealed early hypofluorescence, areas
of non-perfusion, capillary obstruction and dropout,
inner retinal ischemia in the parafoveal and perifoveal
zone corresponding with the cotton-wool spots and
perifoveal capillary leakage in the late frames. The left
eye showed mild cystoid macular edema nasal to the
fovea (Figs. 1, 2). Mild peripapillary leakage was
noted in the late frames of the left eye. Besides a small
hemorrhage peripherally, all other angiographic find-
ings were confined to the posterior pole, namely within
the macula and immediately nasal to the optic disk.
Normal fluorescein transit times were observed. The
degree of macular ischemia and perifoveal capillary
dropout was more pronounced in the left eye in
keeping with the objective visual acuity loss in that
eye. These clinical findings, together with her medical
history, were consistent with Purtscher-like retinopa-
thy. At the time of referral to our clinic, she was
awaiting a second living donor renal transplantation.
The ophthalmic findings provided evidence that the
hemolytic uremic syndrome was undertreated and
indirect evidence that she had uncontrolled systemic
complement activation. In order to prevent further
progression of her retinopathy, and due to the severe
loss of vision in her left eye, treatment with
eculizumab was initiated. Eculizumab, a C5 comple-
ment inhibitor, has been praised as highly effective in
the treatment of hemolytic uremic syndrome, also
after transplantation. After 4 months, while on chronic
eculizumab therapy, a transplantectomy was per-
formed followed by a second renal transplantation.
Both procedures proceeded uneventfully.
On follow-up, she reported a steady continuous
improvement of her visual acuity. Five days after
eculizumab administration, best corrected visual acu-
ity was stable in her right eye and pinhole visual acuity
improved to 20/50?2 in her left eye. Fundus exami-





Fig. 1 Retinal photographs and fluorescein angiogram appear-
ance at initial presentation. a Fundus appearance at presentation.
Note the diffuse retinal nerve fiber layer infarcts, inner retinal
ischemia and scattered retinal hemorrhages. Visual acuity was
20/15 and 20/200-2 in the right and left eye, respectively.
b Mid-phase intravenous fluorescein angiogram of the same
patient at initial presentation. Note the parafoveal and perifoveal
areas of capillary obstruction and retinal ischemia correspon-
dent to the areas of inner retinal ischemia seen in the fundus
picture. c Mid- to late-phase fluorescein angiogram in the same
patient. Note the parafoveal pericapillary staining and mild
macular edema with late leakage in the left eye. Angiographic
findings were mostly confined to the macula and immediately
nasal to the optic disk
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wool spots, and optical coherence tomography showed
total resolution of the cystoid macular edema in the
left eye (Fig. 2). On the 14th day after treatment, she
reported total resolution of all her previous visual
complaints. Best corrected visual acuity was stable in
her right eye and had improved to 20/15-2 in her left
eye. Fundus examination revealed an improvement of
all clinical findings, including the nerve fiber layer
infarcts, flame-shaped hemorrhages and macular
edema. She was referred back to her local ophthal-
mologist. At 18 months, visual acuity remained
stable and no visual complaints were reported (Fig. 3).
Conclusions
This single case describes the favorable visual
outcome achieved after systemic treatment with
eculizumab in a patient with severe Purtscher-like
retinopathy secondary to familial aHUS and CFH
mutation. In our view, the retinal findings were
secondary to uncontrolled systemic complement acti-
vation and as a result complement-mediated leukoem-
bolization and/or complement activation of the
coagulation cascade in endothelial cells with ensuing
development of a prothrombotic state (Fig. 4).
Leukoembolization as a cause of embolic retinal
occlusion has been proposed as a potential pathogenic
mechanism in Purtscher-like retinopathy [6, 48, 49].
However, recent experimental studies suggest
endothelial activation of the coagulation cascade by
complement with formation of microthrombi as the
most plausible mechanism in the pathogenesis of
aHUS [50]. Likewise, we propose this can be extrap-
olated not only to our case, but to all cases of
complement-driven Purtscher-like retinopathy. As
previously mentioned, the patient was known to carry
a mutation in the CFH gene which codes for a serum
protein that regulates the alternative pathway of the
complement system in the fluid phase as well as on
host cell surfaces by binding through C3b and
glycosaminoglycans via its C-terminal domain [51].
Mutations in the CFH gene of patients with aHUS are
usually heterozygous in nature and cluster in C-ter-
minal domain 19–20. This particular mutation, also
found in this patient, results in normal levels of a
folded, abnormal protein, that is unable to bind and
regulate complement on host cells and platelets.
Animal studies have confirmed development of aHUS
with high C3 plasma levels in mice lacking the
C-terminal end domain of factor H [52]. In contrast,
complete CFH knockout mice develop a different
renal disease pattern, namely membranoproliferative
glomerulonephritis [53]. These studies support the
evidence that the mutant CFH present in this patient is
unable to bind and control complement activation on
the glomerular endothelium, basement membrane,
platelets and the retinal endothelium, with subsequent
development of a procoagulant state that in turn
resulted in the development of aHUS and Purtscher-
like retinopathy.
Eculizumab, a monoclonal antibody directed
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Fig. 2 Optical coherence tomography findings at initial pre-
sentation and at day 6 and 15. Inner retinal ischemia was evident
in both eyes, corresponding to the cotton-wool spots demon-
strated in the color photographs. The right eye, with normal
visual acuity at presentation, had no evident macular edema.
The left eye, with severe visual acuity loss, had mild cystoid
macular edema which regressed rapidly after eculizumab
administration. At day 15, visual acuity in the left eye had
improved significantly alongside resolution of the macular
edema and inner retinal ischemia
OD OS 
Fig. 3 Retinal photographs and optical coherence tomography
18 months after initial presentation. Color photographs of the
right and left maculae show a normal appearance, albeit a
significant thinning is evident on optical coherence tomography.
The patient is asymptomatic and has normal visual acuity (20/15
in the right eye and 20/20/15-2 in the left eye)
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of the terminal complement cascade and the genera-
tion of effector molecules C5a and C5b-9. The ability
of eculizumab to suppress complement activity in
native and transplanted kidney has revolutionized the
care of patients with aHUS [54–56]. Without attenu-
ation of complement activity, either through plasma-
pheresis, kidney–liver transplant (CFH and other
complement factors are produced in the liver), or
eculizumab, disease recurrence occurs in approxi-
mately 80% of CFH mutation carriers after renal
transplantation since an isolated kidney allograft does
not correct the underlying genetic defect [57].
We hypothesize that complement inhibition by
means of eculizumab triggered the rapid resolution of
clinical findings and dramatic restoration of visual
acuity in this patient. We consider it unlikely that an
expectant management or other treatment options such
as dosage increase of systemic corticosteroids would
have resulted in a similar outcome. Nevertheless, we






































Fig. 4 Proposed pathogenic mechanisms of Purtscher-like
retinopathy secondary to uncontrolled complement activation.
The alternative pathway activates formation of C3b by C3; C3b
interacts with factor B which is subsequently cleaved by factor
D to form the alternative pathway C3 convertase (C3bBb). This
enzyme complex is covalently attached to the target via C3b
while Bb is the catalytic serine protease subunit. Factor H
regulates the alternative pathway by preventing the interaction
of C3b with factor B, interacting with factor I-mediated
cleavage of C3b and dissociating the C3 convertase of the
alternative pathway (not shown). Unchecked, the terminal
complement pathway is then activated with release of the
complement anaphylatoxin C5a and formation of the membrane
attack complex (MAC). Eculizumab binds C5 which is then
unable to enter the C5 convertase (C3bBbC3b), impeding
cleavage into the effector molecules, C5a and C5b, and
assembly of the terminal complement complex (C5b-9). This
leads to exocytosis of adhesion molecules [P-selectin (P-sel)]
and von Willebrand factor (VWF) which in turn lead to platelet
adhesion and aggregation, expression of tissue factor and
activation of the coagulation cascade. Cell detachment exposes
the subendothelial matrix, facilitating binding of VWF to
collagen with ensuing amplification of the coagulation state.
Platelet aggregates release procoagulant microvesicles that
contain tissue factor. Receptors for C3a and C5a [C3a receptor
(C3aR) and C5a receptor (C5aR)] in polymorphonuclear
leukocytes and monocytes, bind these anaphylatoxins and
enhance the release of cytokines and eicosanoids contributing
to an increase in vascular permeability, vasodilation, leukocyte
extravasation and potentially formation of leukocyte aggregates
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on results obtained with only one patient. Confirma-
tion of clinical efficacy requires validation from a
larger clinical study. In this patient, plasmapheresis
was considered as a possible treatment option; how-
ever, this would not have had an effect on complement
activation which would have resulted in perpetuation
of renal and (possibly) retinal findings. Furthermore,
the therapeutic effect of systemic corticosteroids in
severe Purtscher-like retinopathy is inconsistent, with
most studies confirming no differences in visual
outcome [1, 4]. Interestingly, this patient developed
Purtscher-like retinopathy while on systemic corticos-
teroids, albeit at a low dosage. It has been suggested
that corticosteroids may be inefficient in cases of
Purtscher-like retinopathy that are primarily triggered
by thrombotic microangiopathy, such as in aHUS [58].
Solely targeting the inflammatory component will not
affect microembolization since other complex patho-
genic events such as hemostasis, thrombosis and
complement dysregulation will remain unanswered
[58].
Several clinical parameters support the favorable
effect of eculizumab in this particular patient. First,
pronounced improvement of visual acuity occurred
rapidly after initiation of eculizumab (20/200-2 visual
acuity at time of diagnosis improving to 20/15, 8
Snellen lines improvement, 14 days after initial
examination). Early resolution of clinical findings is
associated with better final visual outcomes [2].
Evidence shows spontaneous visual improvement of
at least 2 Snellen lines is likely to occur in half of
cases; however, such improvement occurs mostly in
patients with better visual acuity at presentation,
whereas poor visual acuity at presentation, such as
observed in this patient, is regarded as a poor
prognostic sign for visual improvement [2]. Secondly,
this patient had other established poor prognostic
criteria [4], namely female gender and intraretinal
macular edema at presentation.
Severe visual loss in Purtscher and Purtscher-like
retinopathies is likely secondary to macular edema [4].
Moreover, the duration of retinal changes is the most
important parameter for full recovery of vision and
prevention of secondary development of retinal pig-
ment epithelium and retinal nerve fiber layer atrophy
with subsequent loss of differentiation between retinal
layers [59]. Therefore, early reduction of macular
edema should be a priority in order to prevent
progression to end-stage degenerative changes.
Mutations in complement-associated genes, and
particularly in the CFH gene, have been shown to be
associated with age-related macular degeneration
(AMD), one of the leading causes of blindness
worldwide [60]. Several mutations in complement-
associated genes reported in patients with aHUS
patients, such as Arg1210Cys in CFH, were found to
confer a high risk of AMD development [61]. The
relevance of this shared genetic association between
two distinct clinical phenotypes remains unknown.
Retrospective analyses of AMD databases did not
reveal a higher incidence of renal disorders in carriers
of complement gene mutations known to cause both
aHUS and AMD [62]. On the other hand, patients
afflicted with membranoproliferative glomeru-
lonephritis type 2 (MPGN2), a renal disease that is
also associated with CFH mutations, show AMD-like
features [63]. This suggests compound (genetic or
environmental) factors may influence the final clinical
outcome. Indeed, AMD and MPGN2 share a common
pathogenic mechanism, i.e., the deposition of com-
plement-containing material beneath the retinal pig-
ment epithelium in AMD and along the glomerular
basement membrane in MPGN2 [63]. On the other
hand, the pathogenic mechanisms causative of
Purtscher-like retinopathy are shared with those of
aHUS, namely endothelial injury, activation of the
coagulation cascade and ultimately thromboembolic
microangiopathy [52]. Moreover, aHUS patients may
carry multiple complement factor gene mutations,
which could imply different cellular pathogenic
mechanisms [64]. Cross-phenotype studies are
required in order to understand similarities and
differences in complement-mediated pathogenic
mechanisms of both aHUS and AMD. This could
elucidate the effects of eculizumab and other comple-
ment-modulating agents in the treatment of AMD and
other ophthalmic diseases. A recent phase 2 study
demonstrated that eculizumab failed to arrest progres-
sion of geographic atrophy (GA) when administered
for 24 weeks to patients with dry AMD (COMPLETE
study) [65]. It is likely that, although complement
dysregulation is knowingly associated with AMD,
pathogenesis and progression of GA may occur
independently of complement overactivation [66]. In
our case report, uncontrolled complement activation
had a direct effect as a facilitator and trigger of the
retinal thromboembolic microangiopathy, and there-
fore, it is highly probable that local complement
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inhibition by systemic eculizumab enabled the rapid
resolution of the retinal microembolization with
ensuing resolution of the intraretinal macular edema.
These complement-mediated effects differ from those
attributed to the complement pathway in diseases
characterized by deposition of extracellular material
such as AMD and MPGN2. Complement inhibition
has been demonstrated to occur within 1 h after
administration of eculizumab [55]. Therefore, eculi-
zumab may be more efficacious in suppressing acute
complement-mediated changes such as thromboem-
bolic microangiopathy of retinal and renal vessels, as
opposed to chronic changes induced by uncontrolled
complement activation such as in AMD. The authors
of the COMPLETE study argue that intravitreal
administration of eculizumab might have resulted in
a more favorable outcome. Our case provides indirect
evidence that systemic eculizumab, at the adminis-
tered dosage, does reach therapeutic concentrations at
the level of the choroid and is able to penetrate the
RPE and retina. In addition, the dosing regimen used
for treatment of aHUS has been shown to reach drug
complement-inhibiting concentrations in the periph-
eral blood [56].
The description of this case raises the possibility that
eculizumab may be a valid therapeutic strategy in
severe cases of Purtscher-like retinopathy in which the
primary pathogenic trigger is attributed to dysregulated
complement activity. The benefit of intervention over
expectant management can only be convincingly
assessed with a randomized clinical trial, which, given
the rarity of the disease and the extreme high cost of the
drug (about US $350.000 per patient per year), is
unlikely. The dramatic and rapid visual recovery
demonstrated in this patient, even in the presence of
established poor prognostic signs, namely poor visual
acuity at presentation, intraretinal macular edema and
female gender, provides convincing evidence that
eculizumabwas causally related to the attained superior
outcome. To the best of our knowledge, this is the first
report in the literature of eculizumab as a potential
therapeutic strategy in Purtscher-like retinopathy.
Compliance with ethical standards
Conflict of interest Author JERC declares that he has no
conflict of interest. Author ROS declares that he has no conflict
of interest. Author MO declares that he has no conflict of
interest. Author FJB declares that she has no conflict of interest.
Author MS declares that she has no conflict of interest.
Human and animal participants All procedures performed
in studies involving human participants were in accordance with
the ethical standards of the institutional and national research
committee and with the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all
individual participant included in the study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you
give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if
changes were made.
References
1. Agrawal A, McKibbin MA (2006) Purtscher’s and Purt-
scher-like retinopathies: a review. Surv Ophthalmol
51(2):129–136. doi:10.1016/j.survophthal.2005.12.003
2. Agrawal A, McKibbin M (2007) Purtscher’s retinopathy:
epidemiology, clinical features and outcome. Br J Oph-
thalmol 91(11):1456–1459. doi:10.1136/bjo.2007.117408
3. Pina JP, Ssi-Yan-Kai K, de Monchy I, Charpentier B, Offret
H, Labetoulle M (2008) Purtscher-like retinopathy: case
report and review of the literature. J Fr D Ophtalmol
31(6):609–613
4. Miguel AIM, Henriques F, Azevedo LFR, Loureiro AJR,
Maberley DAL (2013) Systematic review of Purtscher’s and
Purtscher-like retinopathies. Eye 27(1):1–13. doi:10.1038/
eye.2012.222
5. BehrensbaumannW, ScheurerG (1991)M-Purtscher—range
of clinical manifestations and pathogenesis. Klin Monatsbl
Augenh 198(2):99–107. doi:10.1055/s-2008-1045938
6. Scheurer G, Praetorius G, Damerau B, Behrens-Baumann
W (1992) Vascular occlusion of the retina: an experimental
model. I. Leukocyte aggregates. Graefes Arch Clin Exp
Ophthalmol 230(3):275–280
7. Schroer H, Scheurer G, Behrens-Baumann W (1992) Vas-
cular occlusion of the retina–an experimental model. II.
Platelet aggregates. Graefes Arch Clin Exp Ophthalmol
230(3):281–285
8. Wilkinson WS, Morgan CM, Baruh E, Gitter KA (1989)
Retinal and choroidal vascular occlusion secondary to cor-
ticosteroid embolisation. Br J Ophthalmol 73(1):32–34
9. Lemagne JM, Michiels X, Vancausenbroeck S, Snyers B
(1990) Purtscher-like retinopathy after retrobulbar anes-
thesia. Ophthalmology 97(7):859–861
10. Blodi BA, Williams CA (1997) Purtscher-like retinopathy
after uncomplicated administration of retrobulbar anesthe-
sia. Am J Ophthalmol 124(5):702–703
11. Lim BA, Ang CL (2001) Purtscher-like retinopathy after
retrobulbar injection. Ophthalmic Surg Las 32(6):477–478
12. Blodi BA, JohnsonMW, Gass JD, Fine SL, Joffe LM (1990)




13. Lai JC, Johnson MW, Martonyi CL, Till GO (1997) Com-
plement-induced retinal arteriolar occlusions in the cat.
Retina 17(3):239–246
14. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS
(1978) Oxygen radicals mediate endothelial cell damage by
complement-stimulated granulocytes. An in vitro model of
immune vascular damage. J Clin Invest 61(5):1161–1167.
doi:10.1172/JCI109031
15. Nautiyal A, Amescua G, Jameson A, Gradowski JF, Hong
FY, Doft B (2009) Sudden loss of vision: Purtscher
retinopathy in multiple myeloma. Can Med Assoc J
181(12):E277–E277. doi:10.1503/cmaj.081968
16. Harrison TJ, Abbasi CO, Khraishi TA (2011) Purtscher
retinopathy: an alternative etiology supported by computer
fluid dynamic simulations. Invest Ophthalmol Vis Sci
52(11):8102–8107. doi:10.1167/iovs.11-7734
17. Stewart MW, Brazis PW, Guier CP, Thota SH, Wilson SD
(2007) Purtscher-like retinopathy in a patient with HELLP
syndrome. Am J Ophthalmol 143(5):886–887. doi:10.1016/
j.ajo.2006.12.005
18. Mayer C, Khoramnia R (2011) Purtscher-like retinopathy
caused by acute pancreatitis. Lancet 378(9803):1653.
doi:10.1016/S0140-6736(11)60474-1
19. Becheur H, Machevin L, Mostefa-Kara N, Zahedi R (2001)
Purtscher’ ischemic retinopathy consecutive to an acute
pancreatitis. Gastroenterol Clin Biol 25(10):922–924
20. Bui SK, O’Brien JM, Cunningham ET Jr (2001) Purtscher
retinopathy following drug-induced pancreatitis in an HIV-
positive patient. Retina 21(5):542–545
21. Fumex L, Boizard Y, Burillon C, Denis P (2004) Purtscher
retinopathy in acute alcoholic pancreatitis. A case report.
J Fr Ophtalmol 27(8):927–931
22. Carrera CR, Pierre LM, Medina FM, Pierre-Filho Pde T
(2005) Purtscher-like retinopathy associated with acute
pancreatitis. Sao Paulo Med J 123(6):289–291. doi:10.
1590/S1516-31802005000600008
23. Krahulec B, Stefanickova J, Hlinst’akova S, Hirnerova E,
Kosmalova V, Hasa J, Pesko K, Strmen P, Dukat A (2008)
Purtscher-like retinopathy–a rare complication of acute
pancreatitis. Vnitr Lek 54(3):276–281
24. Bhan K, Ashiq A, Aralikatti A, Menon KV, McKibbin M
(2008) The incidence of Purtscher retinopathy in acute
pancreatitis. Br J Ophthalmol 92(1):151–153. doi:10.1136/
bjo.2006.112847
25. Jeon SY, Jung E, Seol HJ, Hur YJ (2013) Development of
Purtscher-like retinopathy after pre-eclampsia combined
with acute pancreatitis. Obstet Gynecol Sci 56(4):261–264.
doi:10.5468/ogs.2013.56.4.261
26. Tabandeh H, Rosenfeld PJ, Alexandrakis G, Kronish JP,
ChaudhryNA (1999) Purtscher-like retinopathy associatedwith
pancreatic adenocarcinoma. Am J Ophthalmol 128(5):650–652
27. Wu C, Dai RP, Dong FT, Wang Q (2014) Purtscher-like
retinopathy in systemic lupus erythematosus. Am J Oph-
thalmol 158(6):1335–1341. doi:10.1016/j.ajo.2014.09.001
28. Stoumbos VD, Klein ML, Goodman S (1992) Purtscher’s-
like retinopathy in chronic renal failure. Ophthalmology
99(12):1833–1839
29. Zwolinska D, Medynska A, Galar A, Turno A (2000) Purt-
scher-like retinopathy in nephrotic syndrome associated with
mild chronic renal failure. Pediatr Nephrol 15(1–2):82–84
30. Ong T, Nolan W, Jagger J (2005) Purtscher-like retinopathy
as an initial presentation of thrombotic thrombocytopenic
purpura: a case report. Eye (Lond) 19(3):359–361. doi:10.
1038/sj.eye.6701491
31. Patel MR, Bains AK, O’Hara JP, Kallab AM, Marcus DM
(2001) Purtscher retinopathy as the initial sign of thrombotic
thrombocytopenic purpura/hemolytic uremic syndrome.
Arch Ophthalmol 119(9):1388–1389
32. Power MH, Regillo MC, Custis PH (1997) Thrombotic
thrombocytopenic purpura associated with purtscher
retinopathy. Arch Ophthalmol 115(1):128–129
33. Tajunisah I, Patel DK, Subrayan V (2010) Purtscher
retinopathy as an initial presentation of thrombotic throm-
bocytopenic purpura. J Thromb Thrombolysis
30(1):112–113. doi:10.1007/s11239-009-0399-y
34. Lauer AK, Klein ML, Kovarik WD, Palmer EA (1998)
Hemolytic uremic syndrome associated with Purtscher-like
retinopathy. Arch Ophthalmol 116(8):1119–1120
35. Myers JP, Di Bisceglie AM, Mann ES (2001) Cryoglobu-
linemia associated with Purtscher-like retinopathy. Am J
Ophthalmol 131(6):802–804
36. Sauer A, Nasica X, Zorn F, Petitjean P, Bader P, Speeg-
Schatz C, Lenoble P (2007) Cryoglobulinemia revealed by a
Purtscher-like retinopathy. Clin Ophthalmol 1(4):555–557
37. Chebil A, Mammouri R, Abdallah MB, El Matri L (2016)
Purtscher-like Retinopathy as a Rare Presentation of Cryo-
globulinemia. Middle East Afr J Ophthalmol
23(2):219–221. doi:10.4103/0974-9233.177409
38. Hollo G (2008) Frequency of Purtscher’s retinopathy. Br J
Ophthalmol 92(8):1159
39. Yan Y, Shen X (2013) Purtscher-like retinopathy associated
with dermatomyositis. BMC Ophthalmol 13:36. doi:10.
1186/1471-2415-13-36
40. Atabay C, Kansu T, Nurlu G (1993) Late visual recovery
after intravenous methylprednisolone treatment of Purt-
scher’s retinopathy. Ann Ophthalmol 25(9):330–333
41. Nautiyal A, Amescua G, Jameson A, Gradowski JF, Hong F,
Doft B (2009) Sudden loss of vision: Purtscher retinopathy
in multiple myeloma. CMAJ 181(12):E277. doi:10.1503/
cmaj.081968
42. Wang AG, Yen MY, Liu JH (1998) Pathogenesis and neu-
roprotective treatment in Purtscher’s retinopathy. Jpn J
Ophthalmol 42(4):318–322
43. Constantinescu AR, Bitzan M, Weiss LS, Christen E,
Kaplan BS, Cnaan A, Trachtman H (2004) Non-entero-
pathic hemolytic uremic syndrome: causes and short-term
course. Am J Kidney Dis 43(6):976–982. doi:10.1053/j.
ajkd.2004.02.010
44. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic
syndrome. N Engl J Med 361(17):1676–1687. doi:10.1056/
NEJMra0902814
45. Laure AK, Klein ML, Kovarik WD, Palmer EA (1998)
Hemolytic uremic syndrome associated with purtscher-like
retinopathy. Arch Ophthalmol-Chic 116(8):1119–1120
46. Patel MR, Bains AK, O’Hara JP, Kallab AM, Marcus DM
(2001) Purtscher retinopathy as the initial sign of thrombotic
thrombocytopenic purpura/hemolytic uremic syndrome.
Arch Ophthalmol-Chic 119(9):1388–1389
47. Sturm V, Menke MN, Landau K, Laube GF, Neuhaus TJ
(2010) Ocular involvement in paediatric haemolytic
Int Ophthalmol
123
uraemic syndrome. Acta Ophthalmol 88(7):804–807.
doi:10.1111/j.1755-3768.2009.01552.x
48. Jacob HS, Goldstein IM, Shapiro I, Craddock PR, Ham-
merschmidt DE, Weissmann G (1981) Sudden blindness in
acute pancreatitis. Possible role of complement-induced
retinal leukoembolization. Arch Intern Med 141(1):
134–136
49. Shapiro I, Jacob HS (1982) Leukoembolization in ocular
vascular occlusion. Ann Ophthalmol 14(1):60–62
50. Noris M, Remuzzi G (2015) Glomerular diseases dependent
on complement activation, including atypical hemolytic
uremic syndrome, membranoproliferative glomeru-
lonephritis, and C3 Glomerulopathy: core curriculum 2015.
Am J Kidney Dis 66(2):359–375. doi:10.1053/j.ajkd.2015.
03.040
51. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton
CJ, Blaum BS, Lyon M, Uhrin D, Barlow PN (2008) A new
map of glycosaminoglycan and C3b binding sites on factor
H. J Immunol 181(4):2610–2619
52. PickeringMC, de Jorge EG,Martinez-Barricarte R, Recalde
S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook
HT, de Cordoba SR, Botto M (2007) Spontaneous hemo-
lytic uremic syndrome triggered by complement factor H
lacking surface recognition domains. J Exp Med
204(6):1249–1256. doi:10.1084/jem.20070301
53. Pickering MC, Cook HT, Warren J, Bygrave AE, Moss J,
Walport MJ, Botto M (2002) Uncontrolled C3 activation
causes membranoproliferative glomerulonephritis in mice
deficient in complement factor H. Nat Genet
31(4):424–428. doi:10.1038/ng912
54. Fakhouri F, Hourmant M, Campistol JM, Cataland SR,
Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F,
Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bed-
rosian CL, Legendre CM (2016) Terminal complement
inhibitor eculizumab in adult patients with atypical hemo-
lytic uremic Syndrome: a single-arm, open-label trial. Am J
Kidney Dis 68(1):84–93. doi:10.1053/j.ajkd.2015.12.034
55. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S,
Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K,
Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O,
Herthelius M, Hourmant M, Karpman D, Lebranchu Y,
Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M,
Remuzzi G, Richard T, Sberro-Soussan R, Severino B,
Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T,
Loirat C (2013) Terminal complement inhibitor eculizumab
in atypical hemolytic-uremic syndrome. N Engl J Med
368(23):2169–2181. doi:10.1056/NEJMoa1208981
56. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F,
Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E,
Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E,
Remuzzi G (2014) Dynamics of complement activation in
aHUS and how to monitor eculizumab therapy. Blood
124(11):1715–1726. doi:10.1182/blood-2014-02-558296
57. Kavanagh D, Goodship TH (2010) Atypical hemolytic
uremic syndrome. Curr Opin Hematol 17(5):432–438.
doi:10.1097/MOH.0b013e32833cae86
58. Yusuf IH,Watson SL (2013) Purtscher retinopathies: are we
aiming at the wrong target? Eye 27(6):783–785. doi:10.
1038/eye.2013.47
59. Holak HM, Holak S (2007) Prognostic factors for visual
outcome in Purtscher retinopathy. Surv Ophthalmol
52(1):117–118. doi:10.1016/j.survophthal.2006.10.012
60. Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys
I, de Maat MP, Boekhoorn SS, Vingerling JR, Hofman A,
Oostra BA, Uitterlinden AG, Stijnen T, van Duijn CM, de
Jong PT (2006) Complement factor H polymorphism,
complement activators, and risk of age-related macular
degeneration. JAMA 296(3):301–309. doi:10.1001/jama.
296.3.301
61. Zhan XW, Larson DE,Wang CL, Koboldt DC, Sergeev YV,
Fulton RS, Fulton LL, Fronick CC, Branham KE, Bragg-
Gresham J, Jun G, Hu YN, Kang HM, Liu DJ, Othman M,
Brooks M, Ratnapriya R, Boleda A, Grassmann F, von
Strachwitz C, Olson LM, Buitendijk GHS, Hofman A, van
Duijn CM, Cipriani V, Moore AT, Shahid H, Jiang YD,
Conley YP, Morgan DJ, Kim IK, Johnson MP, Cantsilieris
S, Richardson AJ, Guymer RH, Luo HR, Ouyang H, Licht
C, Pluthero FG, Zhang MM, Zhang K, Baird PN, Blangero
J, Klein ML, Farrer LA, DeAngelis MM, Weeks DE, Gorin
MB, Yates JRW, Klaver CCW, Pericak-Vance MA, Haines
JL, Weber BHF, Wilson RK, Heckenlively JR, Chew EY,
Stambolian D, Mardis ER, Swaroop A, Abecasis GR (2013)
Identification of a rare coding variant in complement 3
associated with age-related macular degeneration. Nat
Genet 45(11):1375–1379. doi:10.1038/ng.2758
62. Duvvari MR, Paun CC, Buitendijk GH, Saksens NT,
Volokhina EB, Ristau T, Schoenmaker-Koller FE, van de
Ven JP, Groenewoud JM, van den Heuvel LP, Hofman A,
Fauser S, Uitterlinden AG, Klaver CC, Hoyng CB, de Jong
EK, den Hollander AI (2014) Analysis of rare variants in the
C3 gene in patients with age-related macular degeneration.
PLoS ONE 9(4):e94165. doi:10.1371/journal.pone.
0094165
63. Mullins RF, Aptsiauri N, Hageman GS (2001) Structure and
composition of drusen associated with glomerulonephritis:
implications for the role of complement activation in drusen
biogenesis. Eye 15:390–395
64. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras
Berges L, Lopez-Trascasa M, Sanchez-Corral P, Rodriguez
de Cordoba S (2005) Predisposition to atypical hemolytic
uremic syndrome involves the concurrence of different
susceptibility alleles in the regulators of complement acti-
vation gene cluster in 1q32. Hum Mol Genet
14(5):703–712. doi:10.1093/hmg/ddi066
65. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP,
Gregori G, Penha FM, Moshfeghi AA, Zhang K, Sadda S,
Rosenfeld PJ (2014) Systemic complement inhibition with
eculizumab for geographic atrophy in age-related macular
degeneration: the COMPLETE study. Ophthalmology
121(3):693–701. doi:10.1016/j.ophtha.2013.09.044
66. Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U,
Chew E, Csaky K, Sadda SR, Beckman Initiative for
Macular Research Classification C (2013) Clinical classifi-
cation of age-related macular degeneration. Ophthalmology
120(4):844–851. doi:10.1016/j.ophtha.2012.10.036
Int Ophthalmol
123
